Short antisense oligonucleotides alleviate the pleiotropic toxicity of RNA harboring expanded CGG repeats.
Magdalena DerbisEmre KulDaria NiewiadomskaMichał SekreckiAgnieszka PiaseckaKatarzyna TaylorRenate K HukemaOliver StorkKrzysztof SobczakPublished in: Nature communications (2021)
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an incurable neurodegenerative disorder caused by expansion of CGG repeats in the FMR1 5'UTR. The RNA containing expanded CGG repeats (rCGGexp) causes cell damage by interaction with complementary DNA, forming R-loop structures, sequestration of nuclear proteins involved in RNA metabolism and initiation of translation of polyglycine-containing protein (FMRpolyG), which forms nuclear insoluble inclusions. Here we show the therapeutic potential of short antisense oligonucleotide steric blockers (ASOs) targeting directly the rCGGexp. In nuclei of FXTAS cells ASOs affect R-loop formation and correct miRNA biogenesis and alternative splicing, indicating that nuclear proteins are released from toxic sequestration. In cytoplasm, ASOs significantly decrease the biosynthesis and accumulation of FMRpolyG. Delivery of ASO into a brain of FXTAS mouse model reduces formation of inclusions, improves motor behavior and corrects gene expression profile with marginal signs of toxicity after a few weeks from a treatment.
Keyphrases
- nucleic acid
- mouse model
- oxidative stress
- induced apoptosis
- single cell
- transcription factor
- high resolution
- white matter
- genome wide
- copy number
- cell cycle arrest
- cell therapy
- early onset
- circulating tumor
- resting state
- endoplasmic reticulum stress
- gene expression
- multiple sclerosis
- stem cells
- parkinson disease
- oxide nanoparticles
- functional connectivity
- cancer therapy
- angiotensin ii
- gestational age
- genome wide identification
- subarachnoid hemorrhage
- bone marrow
- signaling pathway